HBME-1 immunostaining in @entity259 especially in XXXX .

@entity1 @entity1377 @entity1885 @entity5 @entity1711 @entity189 @entity2615 @entity1710 @entity5651 @entity3 @entity652 @entity259
It is generally known that even with permanent sections, the differential diagnosis between @entity652 and @entity189 is often difficult to determine. It is not unusual to encounter @entity1 diagnosed with benign @entity652 whose diagnoses have to be changed to @entity5 because of recurrence or @entity3 . As the monoclonal antibody HBME-1 produced by @entity2615 cells has been shown to have reactivity in @entity259 , we investigated the diagnostic usefulness of HBME-1 in @entity5 . Immunohistochemical staining for HBME-1 was performed on 205 various @entity259 using the labeled streptavadin @entity1885 peroxidase method. When @entity1710 - @entity1711 (HE) staining was performed again for this study and all cases were examined in accordance with the WHO Histological Classifications 2nd Edition, 87.2% (54/62) of @entity5651 and 72.6% (45/62) of @entity652 were negative. On the other hand, 84.6% (33/39) of @entity189 and 97.2% (35/36) of @entity1377 were positive. All anaplastic (2/2) and medullary (4/4) @entity189 were negative. Examination in @entity5 had a sensitivity of 84.6%, specificity of 72.6%, positive predictive value of 66.0% and overall accuracy of 77.2%. Among the cases treated as @entity652 clinically, the diagnosis of 13 cases was changed to @entity189 , and 6 cases to @entity1377 for this study. These cases showed strong HBME-1 positivity. Two of the @entity189 cases experienced recurrence. We conclude that immunohistochemical staining with HBME-1 may be useful clinically to pick out cases with a high risk of recurrence in @entity189 , and that benign @entity652 cases need close follow-up.
